XARELTO — Sales to customers (Note 9)
Johnson & Johnson XARELTO — Sales to customers (Note 9) decreased by 6.6% to $642.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.0%, from $690.00M to $642.00M. Over 4 years (FY 2021 to FY 2025), XARELTO — Sales to customers (Note 9) shows relatively stable performance with a 1.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption or successful commercial execution, while a decrease may signal patent expiration, increased competition, or declining therapeutic relevance.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product line to extern...
Peer comparison
Comparable to specific drug or product line revenue disclosures found in the segment reporting of other major pharmaceutical companies.
jnj_segment_xarelto_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $569.00M | $636.00M | $644.00M | $508.00M | $609.00M | $689.00M | $667.00M | $578.00M | $637.00M | $625.00M | $525.00M | $518.00M | $587.00M | $592.00M | $676.00M | $690.00M | $621.00M | $635.00M | $687.00M | $642.00M |
| QoQ Change | — | +11.8% | +1.3% | -21.1% | +19.9% | +13.1% | -3.2% | -13.3% | +10.2% | -1.9% | -16.0% | -1.3% | +13.3% | +0.9% | +14.2% | +2.1% | -10.0% | +2.3% | +8.2% | -6.6% |
| YoY Change | — | — | — | — | +7.0% | +8.3% | +3.6% | +13.8% | +4.6% | -9.3% | -21.3% | -10.4% | -7.8% | -5.3% | +28.8% | +33.2% | +5.8% | +7.3% | +1.6% | -7.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's xarelto — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported xarelto — sales to customers (note 9) of $642.00M in Q1 2026.
- How has Johnson & Johnson's xarelto — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's xarelto — sales to customers (note 9) decreased by 7.0% year-over-year, from $690.00M to $642.00M.
- What is the long-term trend for Johnson & Johnson's xarelto — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's xarelto — sales to customers (note 9) has grown at a 1.9% compound annual growth rate (CAGR), from $2.44B to $2.63B.
- What does xarelto — sales to customers (note 9) mean?
- The total revenue earned from selling a specific pharmaceutical product to customers.